These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 19421966

  • 1. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP, McMahon GT.
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [Abstract] [Full Text] [Related]

  • 2. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA, Valiquette G, Schwarcz MD.
    Cardiol Rev; 2009 Jun; 17(4):165-75. PubMed ID: 19525678
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N, Ali MK, Narayan KM.
    Am J Cardiovasc Drugs; 2012 Feb 01; 12(1):7-22. PubMed ID: 22217193
    [Abstract] [Full Text] [Related]

  • 4. Implications of new diabetes treatment trials: should current clinical practice be altered?
    Kravetz JD, Federman DG.
    Postgrad Med; 2009 May 01; 121(3):67-72. PubMed ID: 19491542
    [Abstract] [Full Text] [Related]

  • 5. [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?].
    Mauricio D, Rius F.
    Med Clin (Barc); 2010 Sep 01; 135 Suppl 2():2-5. PubMed ID: 21420530
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N.
    Nutr Metab Cardiovasc Dis; 2009 Nov 01; 19(9):604-12. PubMed ID: 19427768
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA.
    Curr Med Res Opin; 2006 Nov 01; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [Abstract] [Full Text] [Related]

  • 13. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
    Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, Wang KQ, Zou YZ, Ge JB.
    Ann Med; 2010 May 06; 42(4):305-15. PubMed ID: 20429797
    [Abstract] [Full Text] [Related]

  • 14. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
    Miranda VP, Rodrigues MJ, Gonçalves FR, Nunes JP.
    Rev Port Cardiol; 2009 Oct 06; 28(10):1099-119. PubMed ID: 20058777
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities.
    Khamaisi M, Wexler ID, Skrha J, Strojek K, Raz I, Milicevic Z.
    Isr Med Assoc J; 2003 Nov 06; 5(11):801-6. PubMed ID: 14650106
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A.
    Lakartidningen; 2001 Feb 28; 98(9):937-40. PubMed ID: 11292972
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.